AFC-HD AMS Life Science, First Half Ordinary Profit Revised Upward by 14%, Raises Record High Profit Forecast

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Apr 3, 2025 5:25 pm JST Revision

2927 AFC-HD AMS Life Science Co.,Ltd. 【J-GAAP】

Guidance Update Report

AFC-HD AMS Life Science Co.,Ltd. <2927> [TSE Std] announced a performance revision after the market closed on April 3rd (17:25). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending August 2025 (September 2024 to February 2025) has been revised upward 13.8%, from the previous forecast of 1.2 billion yen to 1.36 billion yen (compared to 1.06 billion yen in the same period of the previous year), increasing the growth rate from 13.2% to 28.9%, further surpassing the previous forecast of record-high profits for two consecutive terms.

Furthermore, the full-year ordinary profit forecast remains unchanged from the estimate of 2.2 billion yen(compared to 1.92 billion yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2024 Prev	16,400	1,200	1,200	720	51.2	16	Oct 15, 2024	J-GAAP
Sep - Feb, 2024 New	16,690	1,329	1,366	904	64.3	16	Apr 3, 2025	J-GAAP
Revision Rate	+1.8%	+10.8%	+13.8%	+25.6%	+25.6%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2023	14,542	1,023	1,060	641	45.8	15	Apr 15, 2024	J-GAAP
Sep - Feb, 2024 Guidance	16,690	1,329	1,366	904	64.3	16	Apr 3, 2025	J-GAAP
YoY	+14.8%	+29.9%	+28.9%	+41.0%	+40.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Aug, 2023	25,579	1,636	1,654	1,102	78.5	27.50	Oct 13, 2023	J-GAAP
Aug, 2024	30,185	1,916	1,921	1,252	89.2	30	Oct 15, 2024	J-GAAP
Aug, 2025 Guidance	31,100	2,200	2,200	1,320	93.9	32	Oct 15, 2024	J-GAAP
YoY	+3.0%	+14.8%	+14.5%	+5.4%	+5.3%